Guido Tricot
Concepts (550)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 148 | 2025 | 3082 | 8.570 |
Why?
| | Hematopoietic Stem Cell Transplantation | 28 | 2024 | 610 | 3.320 |
Why?
| | Pyrazines | 20 | 2023 | 188 | 2.440 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 35 | 2024 | 1043 | 2.310 |
Why?
| | Boronic Acids | 19 | 2014 | 180 | 2.270 |
Why?
| | Thalidomide | 28 | 2023 | 378 | 2.260 |
Why?
| | Transplantation, Autologous | 30 | 2024 | 488 | 1.800 |
Why?
| | Antineoplastic Agents | 30 | 2020 | 1232 | 1.800 |
Why?
| | Transplantation Conditioning | 9 | 2019 | 96 | 1.340 |
Why?
| | Drug Resistance, Neoplasm | 17 | 2020 | 350 | 1.310 |
Why?
| | Paraproteinemias | 8 | 2018 | 72 | 1.180 |
Why?
| | Humans | 158 | 2025 | 53246 | 1.100 |
Why?
| | Neoplastic Stem Cells | 5 | 2020 | 90 | 1.100 |
Why?
| | Protease Inhibitors | 6 | 2011 | 59 | 0.980 |
Why?
| | Venous Thrombosis | 7 | 2009 | 91 | 0.960 |
Why?
| | Melphalan | 16 | 2023 | 180 | 0.920 |
Why?
| | Angiogenesis Inhibitors | 9 | 2009 | 186 | 0.920 |
Why?
| | Stem Cell Transplantation | 13 | 2023 | 191 | 0.910 |
Why?
| | Plasma Cells | 12 | 2025 | 234 | 0.910 |
Why?
| | Aged | 59 | 2025 | 10430 | 0.890 |
Why?
| | Prognosis | 34 | 2025 | 2118 | 0.880 |
Why?
| | Gene Expression Regulation, Neoplastic | 13 | 2020 | 868 | 0.870 |
Why?
| | Hematopoietic Stem Cell Mobilization | 5 | 2014 | 63 | 0.860 |
Why?
| | Middle Aged | 61 | 2025 | 13422 | 0.820 |
Why?
| | Alkaline Phosphatase | 5 | 2011 | 92 | 0.780 |
Why?
| | Busulfan | 3 | 2019 | 18 | 0.770 |
Why?
| | Treatment Outcome | 39 | 2022 | 5597 | 0.720 |
Why?
| | Dexamethasone | 16 | 2024 | 429 | 0.690 |
Why?
| | Male | 69 | 2025 | 27444 | 0.650 |
Why?
| | Chromosome Aberrations | 9 | 2008 | 297 | 0.610 |
Why?
| | Female | 65 | 2025 | 28792 | 0.610 |
Why?
| | Thromboembolism | 3 | 2009 | 48 | 0.610 |
Why?
| | Neoplasm Proteins | 6 | 2021 | 330 | 0.580 |
Why?
| | Chromosomes, Human, Pair 13 | 6 | 2008 | 37 | 0.550 |
Why?
| | Gene Expression Profiling | 19 | 2025 | 1112 | 0.540 |
Why?
| | Disease-Free Survival | 14 | 2019 | 466 | 0.530 |
Why?
| | Immunoglobulin Light Chains | 3 | 2016 | 90 | 0.520 |
Why?
| | Survival Rate | 18 | 2019 | 949 | 0.520 |
Why?
| | Bone Remodeling | 2 | 2010 | 154 | 0.520 |
Why?
| | Blood Transfusion | 1 | 2018 | 127 | 0.510 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 5 | 2025 | 123 | 0.510 |
Why?
| | Anticoagulants | 5 | 2009 | 280 | 0.510 |
Why?
| | Immunologic Factors | 5 | 2012 | 117 | 0.500 |
Why?
| | Cell Line, Tumor | 18 | 2023 | 1470 | 0.480 |
Why?
| | Follow-Up Studies | 21 | 2024 | 2318 | 0.480 |
Why?
| | Receptors, Retinoic Acid | 2 | 2013 | 22 | 0.470 |
Why?
| | Antineoplastic Agents, Alkylating | 7 | 2008 | 78 | 0.460 |
Why?
| | Adult | 39 | 2025 | 14541 | 0.460 |
Why?
| | Proteasome Inhibitors | 6 | 2018 | 104 | 0.460 |
Why?
| | IMP Dehydrogenase | 2 | 2006 | 3 | 0.460 |
Why?
| | Clinical Trials as Topic | 9 | 2022 | 466 | 0.450 |
Why?
| | Mycophenolic Acid | 2 | 2006 | 19 | 0.450 |
Why?
| | Combined Modality Therapy | 13 | 2008 | 640 | 0.440 |
Why?
| | Cell Proliferation | 15 | 2020 | 1031 | 0.440 |
Why?
| | Disease Progression | 13 | 2025 | 880 | 0.430 |
Why?
| | Recurrence | 16 | 2018 | 694 | 0.430 |
Why?
| | Retrospective Studies | 19 | 2025 | 6821 | 0.420 |
Why?
| | Apoptosis | 9 | 2019 | 1139 | 0.420 |
Why?
| | Antigens, Neoplasm | 5 | 2007 | 146 | 0.420 |
Why?
| | Antibodies, Monoclonal | 3 | 2015 | 477 | 0.420 |
Why?
| | Up-Regulation | 5 | 2020 | 456 | 0.420 |
Why?
| | Osteogenesis | 3 | 2012 | 374 | 0.410 |
Why?
| | Animals | 30 | 2024 | 13528 | 0.410 |
Why?
| | Survival Analysis | 12 | 2021 | 659 | 0.400 |
Why?
| | Venous Thromboembolism | 3 | 2011 | 78 | 0.400 |
Why?
| | Signal Transduction | 12 | 2020 | 1748 | 0.390 |
Why?
| | Doxorubicin | 8 | 2018 | 248 | 0.390 |
Why?
| | Bone Diseases | 3 | 2012 | 94 | 0.380 |
Why?
| | Thrombosis | 4 | 2012 | 250 | 0.370 |
Why?
| | Neoplasms, Second Primary | 2 | 2024 | 75 | 0.370 |
Why?
| | T-Lymphocytes | 10 | 2024 | 320 | 0.370 |
Why?
| | Central Nervous System Neoplasms | 2 | 2004 | 69 | 0.360 |
Why?
| | Myeloablative Agonists | 5 | 2014 | 32 | 0.360 |
Why?
| | Bone Marrow | 7 | 2022 | 359 | 0.360 |
Why?
| | Oligopeptides | 2 | 2013 | 94 | 0.350 |
Why?
| | Transplantation, Homologous | 6 | 2004 | 154 | 0.340 |
Why?
| | Osteoblasts | 4 | 2007 | 480 | 0.340 |
Why?
| | Risk Factors | 18 | 2018 | 4018 | 0.330 |
Why?
| | Hematopoietic Stem Cells | 2 | 2010 | 189 | 0.330 |
Why?
| | Salvage Therapy | 9 | 2012 | 138 | 0.320 |
Why?
| | Meta-Analysis as Topic | 2 | 2015 | 40 | 0.320 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2008 | 64 | 0.320 |
Why?
| | Mice | 19 | 2024 | 5982 | 0.320 |
Why?
| | Bone Marrow Transplantation | 5 | 2007 | 110 | 0.320 |
Why?
| | Enzyme Inhibitors | 2 | 2019 | 371 | 0.320 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 274 | 0.320 |
Why?
| | Membrane Proteins | 4 | 2017 | 333 | 0.310 |
Why?
| | Ultrasonography, Doppler | 2 | 2007 | 42 | 0.310 |
Why?
| | Prospective Studies | 9 | 2019 | 2412 | 0.300 |
Why?
| | Remission Induction | 10 | 2008 | 222 | 0.300 |
Why?
| | Cell Cycle Proteins | 2 | 2021 | 170 | 0.300 |
Why?
| | Neoplasm, Residual | 4 | 2022 | 171 | 0.300 |
Why?
| | Myelodysplastic Syndromes | 4 | 2007 | 87 | 0.290 |
Why?
| | B-Lymphocytes | 4 | 2021 | 178 | 0.290 |
Why?
| | Aged, 80 and over | 12 | 2025 | 3495 | 0.290 |
Why?
| | Waldenstrom Macroglobulinemia | 3 | 2018 | 38 | 0.290 |
Why?
| | Lymphoma, B-Cell | 3 | 2021 | 60 | 0.280 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 158 | 0.280 |
Why?
| | Immunosuppressive Agents | 3 | 2005 | 253 | 0.280 |
Why?
| | Bone Neoplasms | 1 | 2010 | 188 | 0.280 |
Why?
| | Killer Cells, Natural | 4 | 2024 | 113 | 0.260 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2016 | 1367 | 0.260 |
Why?
| | Brain Diseases, Metabolic | 1 | 2007 | 5 | 0.260 |
Why?
| | Chromosome Deletion | 3 | 2008 | 138 | 0.260 |
Why?
| | Hyperammonemia | 1 | 2007 | 23 | 0.260 |
Why?
| | Proteasome Endopeptidase Complex | 4 | 2018 | 142 | 0.250 |
Why?
| | Amyloidosis | 2 | 2007 | 83 | 0.250 |
Why?
| | Farnesyltranstransferase | 1 | 2006 | 4 | 0.250 |
Why?
| | Thrombophilia | 4 | 2009 | 18 | 0.250 |
Why?
| | Research Design | 1 | 2009 | 373 | 0.250 |
Why?
| | Small Molecule Libraries | 2 | 2019 | 66 | 0.250 |
Why?
| | Hemostasis | 1 | 2007 | 55 | 0.250 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 4 | 2014 | 59 | 0.250 |
Why?
| | Bone and Bones | 1 | 2010 | 501 | 0.240 |
Why?
| | Flow Cytometry | 6 | 2018 | 400 | 0.240 |
Why?
| | Sirolimus | 1 | 2006 | 72 | 0.240 |
Why?
| | Cell Survival | 8 | 2018 | 600 | 0.240 |
Why?
| | Immunotherapy, Adoptive | 4 | 2024 | 163 | 0.230 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2006 | 44 | 0.230 |
Why?
| | Caspases | 1 | 2006 | 101 | 0.230 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2016 | 266 | 0.230 |
Why?
| | Diploidy | 2 | 2004 | 25 | 0.220 |
Why?
| | beta 2-Microglobulin | 5 | 2008 | 39 | 0.220 |
Why?
| | Antibody Formation | 1 | 2005 | 49 | 0.220 |
Why?
| | Religion | 1 | 2005 | 61 | 0.220 |
Why?
| | Activated Protein C Resistance | 4 | 2011 | 10 | 0.210 |
Why?
| | Case-Control Studies | 10 | 2018 | 1212 | 0.210 |
Why?
| | Aneuploidy | 1 | 2004 | 17 | 0.210 |
Why?
| | Enoxaparin | 1 | 2004 | 32 | 0.210 |
Why?
| | Attitude to Health | 1 | 2005 | 193 | 0.200 |
Why?
| | Ubiquitination | 2 | 2021 | 58 | 0.200 |
Why?
| | Adaptation, Psychological | 1 | 2005 | 233 | 0.200 |
Why?
| | Osteolysis | 2 | 2022 | 74 | 0.200 |
Why?
| | Multivariate Analysis | 5 | 2008 | 598 | 0.200 |
Why?
| | Cisplatin | 6 | 2009 | 282 | 0.200 |
Why?
| | Cancer Vaccines | 3 | 2010 | 79 | 0.200 |
Why?
| | Pyrimidines | 3 | 2015 | 206 | 0.190 |
Why?
| | Cell Communication | 2 | 2006 | 73 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2012 | 630 | 0.190 |
Why?
| | Blood Coagulation | 1 | 2003 | 65 | 0.190 |
Why?
| | Mice, Inbred NOD | 6 | 2020 | 90 | 0.190 |
Why?
| | Critical Illness | 1 | 2005 | 316 | 0.190 |
Why?
| | Antigens, CD34 | 1 | 2003 | 76 | 0.190 |
Why?
| | Cytogenetic Analysis | 6 | 2007 | 79 | 0.180 |
Why?
| | Parathyroid Hormone | 3 | 2010 | 149 | 0.180 |
Why?
| | Graft vs Host Disease | 5 | 2010 | 93 | 0.180 |
Why?
| | Leukemia, Myeloid | 1 | 2002 | 40 | 0.180 |
Why?
| | Cyclophosphamide | 4 | 2003 | 178 | 0.180 |
Why?
| | Kidney | 1 | 2007 | 717 | 0.180 |
Why?
| | Bone Resorption | 2 | 2022 | 304 | 0.180 |
Why?
| | STAT3 Transcription Factor | 4 | 2015 | 89 | 0.180 |
Why?
| | Chromosome Disorders | 1 | 2002 | 32 | 0.180 |
Why?
| | Time Factors | 9 | 2016 | 2992 | 0.170 |
Why?
| | Etoposide | 5 | 2009 | 71 | 0.170 |
Why?
| | Logistic Models | 5 | 2018 | 947 | 0.170 |
Why?
| | Hypothyroidism | 1 | 2002 | 58 | 0.170 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2015 | 68 | 0.170 |
Why?
| | Chromosomes, Human, Pair 1 | 3 | 2006 | 95 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2024 | 647 | 0.160 |
Why?
| | Antibodies, Bispecific | 1 | 2022 | 108 | 0.160 |
Why?
| | DNA-Binding Proteins | 2 | 2020 | 423 | 0.160 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2012 | 55 | 0.150 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2019 | 228 | 0.150 |
Why?
| | Neoplasms | 2 | 2009 | 1335 | 0.150 |
Why?
| | Predictive Value of Tests | 5 | 2009 | 933 | 0.150 |
Why?
| | Glucuronidase | 2 | 2018 | 47 | 0.150 |
Why?
| | Hematologic Neoplasms | 2 | 2016 | 101 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2013 | 128 | 0.150 |
Why?
| | Osteoclasts | 4 | 2022 | 428 | 0.150 |
Why?
| | Cytokines | 4 | 2007 | 627 | 0.150 |
Why?
| | Syndecan-1 | 3 | 2017 | 73 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 6 | 2015 | 487 | 0.140 |
Why?
| | Hydrocarbons, Aromatic | 1 | 2018 | 2 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2022 | 312 | 0.140 |
Why?
| | Drug Tolerance | 1 | 2018 | 60 | 0.140 |
Why?
| | Solvents | 1 | 2018 | 32 | 0.140 |
Why?
| | Pyridines | 1 | 2019 | 135 | 0.140 |
Why?
| | Dendritic Cells | 3 | 2010 | 133 | 0.140 |
Why?
| | Jehovah's Witnesses | 1 | 2018 | 6 | 0.140 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2010 | 67 | 0.140 |
Why?
| | Vincristine | 3 | 2003 | 89 | 0.140 |
Why?
| | Cell Differentiation | 4 | 2022 | 681 | 0.140 |
Why?
| | Platelet Count | 3 | 2008 | 68 | 0.130 |
Why?
| | CDC2-CDC28 Kinases | 2 | 2015 | 11 | 0.130 |
Why?
| | Iron | 2 | 2017 | 130 | 0.130 |
Why?
| | Risk Assessment | 5 | 2023 | 1368 | 0.130 |
Why?
| | Occupational Diseases | 1 | 2018 | 82 | 0.130 |
Why?
| | Interleukin-6 | 2 | 2018 | 272 | 0.130 |
Why?
| | Arsenicals | 2 | 2010 | 15 | 0.130 |
Why?
| | Occupational Exposure | 1 | 2018 | 106 | 0.130 |
Why?
| | Pyruvate Kinase | 1 | 2017 | 7 | 0.130 |
Why?
| | Mice, SCID | 5 | 2018 | 180 | 0.130 |
Why?
| | Ascorbic Acid | 1 | 2017 | 26 | 0.130 |
Why?
| | Oxides | 2 | 2010 | 21 | 0.130 |
Why?
| | Drug Combinations | 1 | 2017 | 138 | 0.130 |
Why?
| | Anthropometry | 1 | 2017 | 101 | 0.120 |
Why?
| | RNA Splicing | 1 | 2017 | 43 | 0.120 |
Why?
| | Transcription Factors | 1 | 2020 | 571 | 0.120 |
Why?
| | Glycolysis | 1 | 2017 | 76 | 0.120 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2016 | 15 | 0.120 |
Why?
| | Factor V | 3 | 2011 | 10 | 0.120 |
Why?
| | Immunotherapy | 4 | 2006 | 266 | 0.120 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2016 | 22 | 0.120 |
Why?
| | Tumor Cells, Cultured | 6 | 2019 | 441 | 0.120 |
Why?
| | Fibrinolytic Agents | 2 | 2007 | 132 | 0.120 |
Why?
| | Incidence | 3 | 2009 | 1085 | 0.120 |
Why?
| | MicroRNAs | 1 | 2020 | 397 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 2 | 2014 | 122 | 0.120 |
Why?
| | Reproductive History | 1 | 2015 | 4 | 0.120 |
Why?
| | Hormone Replacement Therapy | 1 | 2015 | 21 | 0.110 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 28 | 0.110 |
Why?
| | Cyclopentanes | 1 | 2015 | 12 | 0.110 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 88 | 0.110 |
Why?
| | Ubiquitins | 1 | 2015 | 18 | 0.110 |
Why?
| | Hemorrhage | 2 | 2007 | 226 | 0.110 |
Why?
| | Postmenopause | 1 | 2015 | 85 | 0.110 |
Why?
| | Receptors, Cell Surface | 1 | 2015 | 109 | 0.110 |
Why?
| | Cation Transport Proteins | 1 | 2015 | 26 | 0.110 |
Why?
| | NF-kappa B | 3 | 2018 | 327 | 0.110 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2014 | 24 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2015 | 81 | 0.110 |
Why?
| | Intestines | 1 | 2016 | 159 | 0.110 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2015 | 87 | 0.110 |
Why?
| | Translocation, Genetic | 3 | 2005 | 266 | 0.100 |
Why?
| | Leukapheresis | 1 | 2014 | 19 | 0.100 |
Why?
| | Transplantation Chimera | 3 | 2003 | 16 | 0.100 |
Why?
| | Myeloma Proteins | 2 | 2020 | 26 | 0.100 |
Why?
| | Antibodies | 2 | 2024 | 147 | 0.100 |
Why?
| | Gene Deletion | 3 | 2004 | 279 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 505 | 0.100 |
Why?
| | Body Mass Index | 1 | 2017 | 717 | 0.100 |
Why?
| | Veratrum Alkaloids | 1 | 2013 | 5 | 0.100 |
Why?
| | Receptor, Parathyroid Hormone, Type 1 | 1 | 2013 | 27 | 0.100 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2013 | 17 | 0.100 |
Why?
| | Biopsy | 2 | 2006 | 600 | 0.100 |
Why?
| | Isoxazoles | 1 | 2013 | 16 | 0.100 |
Why?
| | Sulfones | 1 | 2013 | 24 | 0.100 |
Why?
| | Cystatin M | 2 | 2024 | 17 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 533 | 0.100 |
Why?
| | Hedgehog Proteins | 1 | 2013 | 35 | 0.100 |
Why?
| | Itraconazole | 1 | 2013 | 37 | 0.100 |
Why?
| | Metaphase | 3 | 2008 | 47 | 0.100 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2013 | 59 | 0.100 |
Why?
| | Carrier Proteins | 2 | 2017 | 315 | 0.100 |
Why?
| | Renal Insufficiency | 3 | 2009 | 108 | 0.090 |
Why?
| | Wnt Proteins | 1 | 2013 | 104 | 0.090 |
Why?
| | B-Cell Maturation Antigen | 2 | 2024 | 101 | 0.090 |
Why?
| | Risk | 2 | 2011 | 306 | 0.090 |
Why?
| | Infusions, Intravenous | 2 | 2003 | 211 | 0.090 |
Why?
| | Viremia | 1 | 2012 | 23 | 0.090 |
Why?
| | Drug Delivery Systems | 2 | 2005 | 148 | 0.090 |
Why?
| | Chromosomes, Human, Pair 11 | 2 | 2002 | 56 | 0.090 |
Why?
| | Radiopharmaceuticals | 2 | 2021 | 198 | 0.090 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2021 | 182 | 0.090 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2012 | 48 | 0.090 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2012 | 48 | 0.090 |
Why?
| | Phosphorylation | 2 | 2020 | 533 | 0.090 |
Why?
| | Receptors, KIR | 2 | 2008 | 11 | 0.090 |
Why?
| | Cytomegalovirus Infections | 1 | 2012 | 49 | 0.090 |
Why?
| | Medical Oncology | 1 | 2012 | 97 | 0.090 |
Why?
| | Reoperation | 2 | 2004 | 476 | 0.090 |
Why?
| | Ligands | 2 | 2009 | 203 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 142 | 0.090 |
Why?
| | Alcohol Drinking | 1 | 2013 | 241 | 0.090 |
Why?
| | Inflammation | 1 | 2016 | 653 | 0.090 |
Why?
| | Age Factors | 3 | 2005 | 1136 | 0.080 |
Why?
| | Smoking | 1 | 2014 | 526 | 0.080 |
Why?
| | Tretinoin | 2 | 2009 | 53 | 0.080 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 7 | 0.080 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 18 | 0.080 |
Why?
| | Recombinant Proteins | 2 | 2010 | 489 | 0.080 |
Why?
| | Janus Kinase 1 | 1 | 2010 | 16 | 0.080 |
Why?
| | Down-Regulation | 2 | 2010 | 344 | 0.080 |
Why?
| | Macrophages | 1 | 2013 | 380 | 0.080 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2007 | 56 | 0.080 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2010 | 22 | 0.080 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2010 | 26 | 0.080 |
Why?
| | Neoplasm Staging | 3 | 2015 | 774 | 0.080 |
Why?
| | Authorship | 1 | 2010 | 12 | 0.080 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 84 | 0.080 |
Why?
| | Bone Density Conservation Agents | 1 | 2010 | 75 | 0.080 |
Why?
| | Conflict of Interest | 1 | 2010 | 24 | 0.080 |
Why?
| | Drug Industry | 1 | 2010 | 39 | 0.080 |
Why?
| | Diphosphonates | 1 | 2010 | 92 | 0.080 |
Why?
| | Disclosure | 1 | 2010 | 40 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2021 | 561 | 0.080 |
Why?
| | Chromosome Banding | 2 | 2006 | 24 | 0.070 |
Why?
| | Leukocyte Count | 2 | 2014 | 71 | 0.070 |
Why?
| | Plasmacytoma | 2 | 2011 | 45 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2014 | 412 | 0.070 |
Why?
| | Periodicals as Topic | 1 | 2010 | 63 | 0.070 |
Why?
| | Cell Cycle | 2 | 2010 | 237 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 3 | 2007 | 1587 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2009 | 42 | 0.070 |
Why?
| | Blotting, Western | 3 | 2015 | 587 | 0.070 |
Why?
| | Cryoglobulinemia | 1 | 2008 | 13 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 189 | 0.070 |
Why?
| | Cytogenetics | 1 | 2008 | 23 | 0.070 |
Why?
| | Prednisone | 2 | 2009 | 101 | 0.070 |
Why?
| | Pulmonary Embolism | 1 | 2009 | 83 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 579 | 0.070 |
Why?
| | Neutrophils | 2 | 2014 | 153 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 95 | 0.070 |
Why?
| | Sulfonamides | 1 | 2009 | 139 | 0.070 |
Why?
| | Immunophenotyping | 2 | 2007 | 118 | 0.070 |
Why?
| | Adoptive Transfer | 1 | 2007 | 29 | 0.070 |
Why?
| | Hemoglobins | 1 | 2008 | 114 | 0.070 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2007 | 22 | 0.070 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2007 | 47 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 145 | 0.070 |
Why?
| | Phlebography | 1 | 2007 | 55 | 0.060 |
Why?
| | Fibrinolysis | 1 | 2007 | 6 | 0.060 |
Why?
| | Blood Coagulation Factors | 1 | 2007 | 17 | 0.060 |
Why?
| | Serum Albumin | 2 | 2008 | 56 | 0.060 |
Why?
| | Ammonia | 1 | 2007 | 89 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2007 | 291 | 0.060 |
Why?
| | Biomedical Research | 1 | 2010 | 267 | 0.060 |
Why?
| | Cell Membrane | 1 | 2007 | 233 | 0.060 |
Why?
| | Brain | 2 | 2007 | 1353 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2006 | 370 | 0.060 |
Why?
| | Osteoprotegerin | 1 | 2006 | 53 | 0.060 |
Why?
| | Models, Genetic | 1 | 2006 | 169 | 0.060 |
Why?
| | Guanosine | 1 | 2006 | 7 | 0.060 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2006 | 84 | 0.060 |
Why?
| | Sex Factors | 3 | 2016 | 747 | 0.060 |
Why?
| | Femur Head Necrosis | 1 | 2005 | 18 | 0.060 |
Why?
| | Survivors | 1 | 2006 | 120 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2007 | 196 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2005 | 86 | 0.050 |
Why?
| | Karyotyping | 1 | 2005 | 77 | 0.050 |
Why?
| | Guanosine Triphosphate | 1 | 2004 | 15 | 0.050 |
Why?
| | Gene Duplication | 1 | 2005 | 16 | 0.050 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2005 | 62 | 0.050 |
Why?
| | Tissue Donors | 2 | 2003 | 130 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 246 | 0.050 |
Why?
| | Kidney Transplantation | 1 | 2007 | 204 | 0.050 |
Why?
| | Proteolysis | 2 | 2015 | 105 | 0.050 |
Why?
| | Genomic Instability | 1 | 2005 | 88 | 0.050 |
Why?
| | Thrombophlebitis | 1 | 2004 | 19 | 0.050 |
Why?
| | Tomography, Emission-Computed | 1 | 2004 | 53 | 0.050 |
Why?
| | Ferritins | 1 | 2024 | 38 | 0.050 |
Why?
| | RNA Interference | 2 | 2015 | 181 | 0.050 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2004 | 34 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 15 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 80 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2004 | 333 | 0.050 |
Why?
| | Patient Selection | 1 | 2005 | 273 | 0.050 |
Why?
| | Stem Cell Factor | 1 | 2003 | 7 | 0.050 |
Why?
| | Discitis | 1 | 2003 | 11 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2003 | 158 | 0.050 |
Why?
| | Probability | 1 | 2003 | 171 | 0.050 |
Why?
| | Lymphocyte Transfusion | 1 | 2003 | 10 | 0.050 |
Why?
| | Interferons | 1 | 2002 | 39 | 0.050 |
Why?
| | Cell Count | 1 | 2003 | 141 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| | Anxiety | 1 | 2005 | 321 | 0.050 |
Why?
| | Cyclosporine | 1 | 2003 | 64 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 405 | 0.050 |
Why?
| | Transcriptome | 1 | 2025 | 368 | 0.050 |
Why?
| | Geography | 1 | 2022 | 65 | 0.050 |
Why?
| | Thyroid Function Tests | 1 | 2002 | 28 | 0.050 |
Why?
| | Blood Group Incompatibility | 1 | 2002 | 4 | 0.040 |
Why?
| | Tacrolimus | 1 | 2003 | 61 | 0.040 |
Why?
| | Stromal Cells | 1 | 2002 | 77 | 0.040 |
Why?
| | Administration, Oral | 1 | 2003 | 456 | 0.040 |
Why?
| | ABO Blood-Group System | 1 | 2002 | 16 | 0.040 |
Why?
| | Thyrotropin | 1 | 2002 | 49 | 0.040 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2002 | 11 | 0.040 |
Why?
| | Drug Interactions | 1 | 2002 | 196 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2002 | 193 | 0.040 |
Why?
| | Chromosome Mapping | 3 | 2006 | 145 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 271 | 0.040 |
Why?
| | Cell Division | 1 | 2002 | 289 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2005 | 1569 | 0.040 |
Why?
| | RANK Ligand | 1 | 2022 | 188 | 0.040 |
Why?
| | Graft Survival | 1 | 2002 | 158 | 0.040 |
Why?
| | Acute Disease | 1 | 2002 | 393 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2006 | 1183 | 0.040 |
Why?
| | Cluster Analysis | 3 | 2006 | 238 | 0.040 |
Why?
| | Young Adult | 3 | 2015 | 4514 | 0.040 |
Why?
| | Pain | 1 | 2003 | 353 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2020 | 86 | 0.040 |
Why?
| | Staphylococcal Infections | 1 | 2003 | 271 | 0.040 |
Why?
| | Odds Ratio | 2 | 2016 | 567 | 0.040 |
Why?
| | Depression | 1 | 2005 | 621 | 0.040 |
Why?
| | 3' Untranslated Regions | 1 | 2020 | 55 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2007 | 1099 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2021 | 299 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2019 | 155 | 0.040 |
Why?
| | Antigens, CD | 2 | 2015 | 217 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 232 | 0.040 |
Why?
| | Protein Conformation | 1 | 2019 | 174 | 0.040 |
Why?
| | Bone Marrow Cells | 2 | 2015 | 188 | 0.040 |
Why?
| | Coculture Techniques | 2 | 2012 | 146 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 310 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2018 | 22 | 0.040 |
Why?
| | Antigens, CD19 | 1 | 2018 | 29 | 0.040 |
Why?
| | Microarray Analysis | 1 | 2018 | 69 | 0.040 |
Why?
| | Disease Management | 1 | 2020 | 187 | 0.030 |
Why?
| | Drug Resistance | 1 | 2018 | 71 | 0.030 |
Why?
| | Interferon-gamma | 2 | 2010 | 174 | 0.030 |
Why?
| | Protein Stability | 1 | 2018 | 45 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2018 | 109 | 0.030 |
Why?
| | Epidemiologic Methods | 2 | 2008 | 47 | 0.030 |
Why?
| | Aerobiosis | 1 | 2017 | 13 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 1723 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2017 | 44 | 0.030 |
Why?
| | HLA-A Antigens | 2 | 2007 | 11 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2017 | 78 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2017 | 58 | 0.030 |
Why?
| | Thyroid Hormones | 1 | 2017 | 23 | 0.030 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2016 | 3 | 0.030 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2016 | 6 | 0.030 |
Why?
| | Vaccination | 2 | 2010 | 310 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2017 | 55 | 0.030 |
Why?
| | Genetic Loci | 1 | 2016 | 48 | 0.030 |
Why?
| | Protein Binding | 1 | 2018 | 670 | 0.030 |
Why?
| | Antibodies, Neoplasm | 2 | 2006 | 27 | 0.030 |
Why?
| | Mice, Inbred ICR | 1 | 2016 | 24 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2018 | 910 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2015 | 68 | 0.030 |
Why?
| | Reoviridae | 1 | 2015 | 25 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 132 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 184 | 0.030 |
Why?
| | ras Proteins | 1 | 2015 | 64 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2016 | 149 | 0.030 |
Why?
| | Receptors, Transferrin | 1 | 2015 | 16 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2013 | 1517 | 0.030 |
Why?
| | Side-Population Cells | 1 | 2015 | 3 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2010 | 1133 | 0.030 |
Why?
| | Models, Biological | 1 | 2018 | 737 | 0.030 |
Why?
| | Lentivirus | 1 | 2015 | 17 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2014 | 10 | 0.030 |
Why?
| | Adenine | 1 | 2015 | 29 | 0.030 |
Why?
| | Family | 1 | 2016 | 179 | 0.030 |
Why?
| | Cyclin B | 1 | 2014 | 4 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 138 | 0.030 |
Why?
| | CDC2 Protein Kinase | 1 | 2014 | 15 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 421 | 0.030 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 9 | 0.030 |
Why?
| | Portraits as Topic | 1 | 2014 | 2 | 0.030 |
Why?
| | Cell Lineage | 1 | 2014 | 90 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 147 | 0.030 |
Why?
| | Mitosis | 1 | 2014 | 86 | 0.030 |
Why?
| | beta Catenin | 1 | 2015 | 107 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 99 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2014 | 136 | 0.030 |
Why?
| | Pyrazoles | 1 | 2015 | 123 | 0.030 |
Why?
| | Cell Movement | 1 | 2015 | 279 | 0.020 |
Why?
| | Proportional Hazards Models | 2 | 2006 | 445 | 0.020 |
Why?
| | Patient Safety | 1 | 2014 | 103 | 0.020 |
Why?
| | Peptide Library | 1 | 2013 | 16 | 0.020 |
Why?
| | Receptors, IgG | 1 | 2013 | 23 | 0.020 |
Why?
| | Membrane Glycoproteins | 2 | 2006 | 238 | 0.020 |
Why?
| | Adolescent | 2 | 2014 | 6912 | 0.020 |
Why?
| | Chromosomal Instability | 1 | 2013 | 16 | 0.020 |
Why?
| | Epitopes | 1 | 2013 | 61 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 46 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 234 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2012 | 59 | 0.020 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2012 | 7 | 0.020 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 8 | 0.020 |
Why?
| | Viral Load | 1 | 2012 | 83 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2012 | 69 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2012 | 42 | 0.020 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2012 | 60 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 134 | 0.020 |
Why?
| | Arkansas | 2 | 2008 | 2068 | 0.020 |
Why?
| | Virus Activation | 1 | 2012 | 49 | 0.020 |
Why?
| | Viper Venoms | 1 | 2011 | 6 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2012 | 124 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2011 | 38 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 163 | 0.020 |
Why?
| | Protein C | 1 | 2011 | 20 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2011 | 122 | 0.020 |
Why?
| | Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2010 | 24 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2012 | 179 | 0.020 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2010 | 5 | 0.020 |
Why?
| | CD40 Ligand | 1 | 2010 | 14 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 2010 | 18 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 40 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2010 | 64 | 0.020 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 52 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2004 | 1038 | 0.020 |
Why?
| | Mutation | 1 | 2015 | 1338 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2010 | 214 | 0.020 |
Why?
| | Physician's Role | 1 | 2010 | 49 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 502 | 0.020 |
Why?
| | Education, Medical, Continuing | 1 | 2010 | 76 | 0.020 |
Why?
| | Hyperhomocysteinemia | 1 | 2009 | 29 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2009 | 124 | 0.020 |
Why?
| | Indazoles | 1 | 2009 | 47 | 0.020 |
Why?
| | Safety | 1 | 2009 | 78 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2008 | 26 | 0.020 |
Why?
| | Algorithms | 1 | 2012 | 668 | 0.020 |
Why?
| | Vasculitis | 1 | 2008 | 28 | 0.020 |
Why?
| | Ploidies | 1 | 2008 | 10 | 0.020 |
Why?
| | Haplotypes | 1 | 2008 | 96 | 0.020 |
Why?
| | Twins | 1 | 2007 | 21 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2009 | 729 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 175 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2008 | 152 | 0.020 |
Why?
| | Multigene Family | 1 | 2006 | 50 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 158 | 0.020 |
Why?
| | Blood Proteins | 1 | 2007 | 84 | 0.020 |
Why?
| | Partial Thromboplastin Time | 1 | 2006 | 15 | 0.020 |
Why?
| | Cyclin D | 1 | 2006 | 18 | 0.020 |
Why?
| | Syndecans | 1 | 2006 | 37 | 0.020 |
Why?
| | Cyclins | 1 | 2006 | 38 | 0.020 |
Why?
| | Heterozygote | 1 | 2006 | 89 | 0.010 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 45 | 0.010 |
Why?
| | Proteoglycans | 1 | 2006 | 86 | 0.010 |
Why?
| | Amiloride | 1 | 2005 | 7 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 2005 | 11 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 1016 | 0.010 |
Why?
| | Transduction, Genetic | 1 | 2005 | 44 | 0.010 |
Why?
| | Radiography | 1 | 2007 | 476 | 0.010 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2007 | 208 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 169 | 0.010 |
Why?
| | Neoplasms, Experimental | 1 | 2006 | 112 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 869 | 0.010 |
Why?
| | Interferon-alpha | 1 | 2005 | 53 | 0.010 |
Why?
| | Monocytes | 1 | 2005 | 126 | 0.010 |
Why?
| | Databases, Factual | 1 | 2007 | 742 | 0.010 |
Why?
| | Clone Cells | 1 | 2004 | 76 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2005 | 238 | 0.010 |
Why?
| | Monosomy | 1 | 2003 | 5 | 0.010 |
Why?
| | Fibroblasts | 1 | 2005 | 363 | 0.010 |
Why?
| | Trisomy | 1 | 2003 | 34 | 0.010 |
Why?
| | History, 21st Century | 1 | 2003 | 60 | 0.010 |
Why?
| | History, 20th Century | 1 | 2003 | 97 | 0.010 |
Why?
| | Interphase | 1 | 2003 | 9 | 0.010 |
Why?
| | Plasmapheresis | 1 | 2003 | 12 | 0.010 |
Why?
| | Back Pain | 1 | 2003 | 40 | 0.010 |
Why?
| | United States | 1 | 2013 | 5413 | 0.010 |
Why?
| | Perforin | 1 | 2002 | 12 | 0.010 |
Why?
| | Cohort Studies | 1 | 2006 | 1557 | 0.010 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2002 | 11 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2002 | 25 | 0.010 |
Why?
| | Anemia | 1 | 2003 | 76 | 0.010 |
Why?
| | Red-Cell Aplasia, Pure | 1 | 2002 | 7 | 0.010 |
Why?
| | Quality Assurance, Health Care | 1 | 2003 | 146 | 0.010 |
Why?
| | Prevalence | 1 | 2005 | 1034 | 0.010 |
Why?
| | Erythrocyte Transfusion | 1 | 2002 | 53 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 99 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2002 | 146 | 0.010 |
Why?
| | Graft Rejection | 1 | 2002 | 166 | 0.010 |
Why?
| | Kidney Diseases | 1 | 2003 | 230 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 832 | 0.010 |
Why?
|
|
Tricot's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|